Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease - PubMed (original) (raw)
Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease
Monte S Willis et al. Future Cardiol. 2008 Jan.
Abstract
Over the course of 3 billion heartbeats in an average human lifetime, the heart must maintain constant protein quality control, including the coordinated and regulated degradation of proteins via the ubiquitin-proteasome system (UPS). Recent data highlight the specificity by which the UPS functions in the context of cardiac hypertrophy, ischemic heart disease and cardiomyopathies. Although curbing the appetite of the proteasome through the use of inhibitors in animal models of cardiac disease has proven effective experimentally, recent studies report proteasome inhibition as being cardiotoxic in some patients. Therefore, focusing on specific regulatory components of the proteasome, such as members of the E3 ubiquitin-ligase family of proteins, may hold promise for targeted therapeutics of cardiac disease. This review focuses on the UPS, its specific role in cardiac disease and opportunities for novel therapies.
Keywords: CHIP; MDM2; MuRF1; Velcade™; atrogin-1; bortezomib; cardiac; hypertrophy; ischemia; reperfusion.
Figures
Figure 1. Overview of the ubiquitin-proteasome system
The degradation of proteins via the ubiquitin-proteasome system is dependent on the sequential addition of ubiquitin molecules on targeted protein substrates. (A) Free ubiquitin is activated by the E1 enzyme and transferred to an E2 enzyme. E3 ubiquitin ligases mediate the transfer of the ubiquitin molecule from the E2 to the substrate protein, a process that is repeated, resulting in polyubiquitin chain formation on the protein substrate. Polyubiquitin chains are subsequently recognized by the 26S proteasome, resulting in cleavage of the protein substrate into small peptides and the release of ubiquitin molecules. (B) Homologous polyubiquitin chains formed via linkages at lysine-48 of the presiding ubiquitin molecule result in a chain conformation that is recognized by the 26S proteasome. Conversely, polyubiquitin chains coupled via lysine-63 linkages yield chain conformations that are not recognized by the 26S proteasome; rather, these linkages alter the function of the protein substrate. Lys: Lysine; Ub: Ubiquitin.
Figure 2. Mechanisms of p53-mediated apoptosis
The transcription factor p53 regulates the induction of apoptosis by regulating BAX, PUMA and APAF-1 expression. The permeability of the mitochondria and subsequent release of cytochrome C is regulated by a balance between antiapoptotic (i.e., BCL-2) and proapoptotic (i.e., BAX) factors. The increase of the proapoptotic BAX and its effector molecule, PUMA, in response to p53, interacts with and overcomes the antiapoptotic BCL-2, resulting in the release of mitochondrial cytochrome C. Cytochrome C, together with ATP and APAF-1, acts to activate caspase 9 in the activation of apoptosis through the intrinsic pathway. APAF: Apoptotic protease-activating factor; BAX: BCL-2-associated X protein; BCL-2: B-cell lymphoma-2 protein; CHIP: Carboxyl terminus of Hsp70-interacting protein; MDM: Murine double minute; PUMA: p53-upregulated modulator of apoptosis.
Figure 3. Ubiquitin-proteasome system-mediated resulation of the nuclear factor-κB activation pathway
Activation of the multimeric IKK mediates the phosphorylation of IκB. The modified IκB is then recognized by the SCF-βTrCP E3 ubiquitin ligase and targeted for degradation via the ubiquitin-proteasome system, liberating the p50/p65 nuclear factor (NF)-κB dimer. This results in the exposure of a nuclear localization signal on p50/p65, previously obscured by IκB, promoting the nuclear translocation of p50/p65 and the subsequent activation of the NF-κB transcriptional program. Multiple pathways pertinent to cardiac hypertrophy and failure are activated by NF-κB-mediated transcription, such as cell adhesion, apoptosis, inflammation and immune-response signaling molecules. AGT: Angiotensinogen; CBF: Complement factor B; IAP: Inhibitor of apoptosis protein; ICAM: Intercellular adhesion molecule; IκB: Inhibitor of κB; IKK: IκB kinase complex; P: Phosphate; SAA: Serum amyloid A; SCF-βTrCP: Skip-Cullin-F box β-transducin repeat-containing protein; Ub: Ubiquitin; VCAM: Vascular cell adhesion molecule. Figure adapted from [65,66].
Similar articles
- Into the heart: the emerging role of the ubiquitin-proteasome system.
Willis MS, Patterson C. Willis MS, et al. J Mol Cell Cardiol. 2006 Oct;41(4):567-79. doi: 10.1016/j.yjmcc.2006.07.015. Epub 2006 Sep 1. J Mol Cell Cardiol. 2006. PMID: 16949602 Review. - Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy.
Gupta I, Varshney NK, Khan S. Gupta I, et al. Front Genet. 2018 Aug 21;9:336. doi: 10.3389/fgene.2018.00336. eCollection 2018. Front Genet. 2018. PMID: 30186311 Free PMC article. Review. - The Ubiquitin Proteasome System in Ischemic and Dilated Cardiomyopathy.
Spänig S, Kellermann K, Dieterlen MT, Noack T, Lehmann S, Borger MA, Garbade J, Barac YD, Emrich F. Spänig S, et al. Int J Mol Sci. 2019 Dec 17;20(24):6354. doi: 10.3390/ijms20246354. Int J Mol Sci. 2019. PMID: 31861129 Free PMC article. - Ubiquitin-proteasome system and hereditary cardiomyopathies.
Schlossarek S, Frey N, Carrier L. Schlossarek S, et al. J Mol Cell Cardiol. 2014 Jun;71:25-31. doi: 10.1016/j.yjmcc.2013.12.016. Epub 2013 Dec 28. J Mol Cell Cardiol. 2014. PMID: 24380728 Review. - Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms.
Mearini G, Gedicke C, Schlossarek S, Witt CC, Krämer E, Cao P, Gomes MD, Lecker SH, Labeit S, Willis MS, Eschenhagen T, Carrier L. Mearini G, et al. Cardiovasc Res. 2010 Jan 15;85(2):357-66. doi: 10.1093/cvr/cvp348. Epub 2009 Oct 22. Cardiovasc Res. 2010. PMID: 19850579 Free PMC article.
Cited by
- Sodium fluoride induces skeletal muscle atrophy via changes in mitochondrial and sarcomeric proteomes.
Nagendra AH, Ray A, Chaudhury D, Mitra A, Ranade AV, Bose B, Shenoy P S. Nagendra AH, et al. PLoS One. 2022 Dec 22;17(12):e0279261. doi: 10.1371/journal.pone.0279261. eCollection 2022. PLoS One. 2022. PMID: 36548359 Free PMC article. - Generation of MuRF-GFP transgenic zebrafish models for investigating murf gene expression and protein localization in Smyd1b and Hsp90α1 knockdown embryos.
Li B, Li S, He Q, Du S. Li B, et al. Comp Biochem Physiol B Biochem Mol Biol. 2020 Feb;240:110368. doi: 10.1016/j.cbpb.2019.110368. Epub 2019 Oct 24. Comp Biochem Physiol B Biochem Mol Biol. 2020. PMID: 31669374 Free PMC article. - LRSAM1 E3 ubiquitin ligase: molecular neurobiological perspectives linked with brain diseases.
Mishra R, Upadhyay A, Prajapati VK, Dhiman R, Poluri KM, Jana NR, Mishra A. Mishra R, et al. Cell Mol Life Sci. 2019 Jun;76(11):2093-2110. doi: 10.1007/s00018-019-03055-y. Epub 2019 Mar 2. Cell Mol Life Sci. 2019. PMID: 30826859 Free PMC article. Review. - Increasing Cardiomyocyte Atrogin-1 Reduces Aging-Associated Fibrosis and Regulates Remodeling in Vivo.
Mota R, Parry TL, Yates CC, Qiang Z, Eaton SC, Mwiza JM, Tulasi D, Schisler JC, Patterson C, Zaglia T, Sandri M, Willis MS. Mota R, et al. Am J Pathol. 2018 Jul;188(7):1676-1692. doi: 10.1016/j.ajpath.2018.04.007. Epub 2018 May 23. Am J Pathol. 2018. PMID: 29758183 Free PMC article. - Effects of a Proteasome Inhibitor on Cardiomyocytes in a Pressure-Overload Hypertrophy Rat Model: An Animal Study.
Kim IS, Jo WM. Kim IS, et al. Korean J Thorac Cardiovasc Surg. 2017 Jun;50(3):144-152. doi: 10.5090/kjtcs.2017.50.3.144. Epub 2017 Jun 5. Korean J Thorac Cardiovasc Surg. 2017. PMID: 28593149 Free PMC article.
References
- Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426:895–899. - PubMed
- Bao J, Sato K, Li M, et al. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IκBα degradation. Am J Physiol Heart Circ Physiol. 2001;281:H2612–H2618. - PubMed
- Luss H, Schmitz W, Neumann J. A proteasome inhibitor confers cardioprotection. Cardiovasc Res. 2002;54:140–151. - PubMed
- Pye J, Ardeshirpour F, McCain A, et al. Proteasome inhibition ablates activation of NF-κB in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol. 2003;284:H919–H926. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials